自顶铂基化疗方案引入以来，睾丸癌（TC）患者的生存时间有了显著改善。然而，与一般人口相比，TC患者的死亡风险仍然显著较高。本研究的目的是评估和量化TC诊断后的死亡原因。本研究研究了2000年至2018年间由美国监测、流行病学和结果数据库（SEER）登记和诊断的44,975名TC患者。在本研究中，根据年龄和种族分层分析，计算了TC患者每种死因的标化死亡率（SMR）。 在纳入的参与者中，有3,573人（7.94％）在随访期间死亡。死亡人数最多的比例（38.20％）发生在诊断后1至5年之间。大多数死亡是由于TC本身和其他癌症引起的。对于非恶性疾病，诊断后1年内最常见的死因是意外伤害和不良反应（53人，4.75％），其次是心脏疾病（45人，4.04％）。然而，在诊断后1年以上，最常见的非癌死因是心脏疾病。分层分析结果显示，非西班牙裔白人TC参与者患中风的SMR（0.68，95％置信区间为33.39-38.67）与美国总体相比较低。 尽管TC仍然是TC诊断后最常见的死因，但其他非TC死因在TC患者中也占有相当数量的死亡人数。这些发现有助于TC幸存者了解不同随访期可能出现的各种健康风险。2023年版权所有。Springer Nature旗下BioMed Central Ltd.

After the introduction of cisplatin-based chemotherapy, the survival time of testicular cancer (TC) patients has improved dramatically. However, the overall risk of death in patients with TC remains significantly higher than in the general population. The aim of this study was to assess and quantify the causes of death after TC diagnosis.In total, 44,975 men with TC in the United States diagnosed and registered by the Surveillance, Epidemiology, and End Results (SEER) database during 2000 to 2018 were studied. In this study, standardized mortality rates (SMRs) were calculated for each cause of death in TC individuals and further analyzed in strata according to age and race.Of the included participants, 3,573 (7.94%) died during the follow-up period. The greatest proportion of deaths (38.20%) occurred within 1 to 5 years after diagnosis. Most deaths occurred from TC itself and other cancers. For non-malignant conditions, the most common causes of death within 1 years after diagnosis were accidents and adverse effects (53, 4.75%) followed by diseases of heart (45, 4.04%). However, > 1 years after diagnosis, the most common noncancer causes of death were heart diseases. Results of stratified analysis show that non-Hispanic White TC participants have a lower SMR (0.68, 95% CI, 33.39-38.67) from Cerebrovascular Diseases than the general U.S.Although TC remains the most common cause of death after TC diagnosis, other non-TC causes of death represent a significant number of deaths among TC men. These findings help TC survivors understand the various health risks that may occur at different follow-up periods.© 2023. BioMed Central Ltd., part of Springer Nature.